- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05507541
TTI-622 and TTI-621 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Randomized Phase 2 Study With Safety Run-In of PD-1 Inhibitor and IgG4 SIRPα-Fc Fusion Protein (TTI-622) and PD-1 Inhibitor and IgG1 SIRPα-Fc Fusion Protein (TTI-621) in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
Study Overview
Status
Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma
- Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
- Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
- Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
- Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
- Recurrent High Grade B-Cell Lymphoma
- Refractory High Grade B-Cell Lymphoma
- Recurrent Grade 3b Follicular Lymphoma
- Refractory Grade 3b Follicular Lymphoma
- Recurrent Intravascular Large B-Cell Lymphoma
- Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Refractory Intravascular Large B-Cell Lymphoma
- Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
- Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
- Recurrent ALK Positive Large B-Cell Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation
- Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified
- Refractory ALK Positive Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation
- Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified
- Refractory Primary Mediastinal Large B-Cell Lymphoma
- Recurrent Gray Zone Lymphoma
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the toxicities of ontorpacept (TTI-621) or SIRPa-IgG4-Fc Fusion Protein TTI-622 (TTI-622) combined with pembrolizumab and to identify the recommended Phase 2 dose (RP2D) of TTI-621 and TTI-622, each combined with pembrolizumab. (Safety run in) II. To estimate preliminary efficacy of pembrolizumab in combination with TTI-621 (Arm A) or TTI-622 (Arm B) as measured by overall response rate (ORR). (Phase II).
SECONDARY OBJECTIVE:
I. To estimate efficacy of pembrolizumab in combination with TTI-621 or TTI-622 as measured by duration of response (DOR), progression free survival (PFS), and overall survival (OS).
CORRELATIVE OBJECTIVE:
I. Correlation of biomarkers measured in serial peripheral blood samples and tumor tissues with clinical responses, which may include but are not limited to: SIRPalpha expression, monocyte/macrophage markers in tumor micro-environment, tumor infiltrating lymphocytes (TILs), PD-1/PDL-1 expression.
OUTLINE: Patients are assigned to 1 of 2 arms.
ARM A: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1 of each cycle and TTI-621 IV over 60-120 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo positron emission tomography/computed tomography (PET/CT) scans or CT scans of the chest, abdomen, and pelvis prior to cycle 3 and every 4 cycles thereafter. If no disease progression after cycle 12, patients then receive pembrolizumab IV over 30 minutes on days 1 of each cycle and TTI-621 IV over 60-120 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 23 cycles in the absence of disease progression or unacceptable toxicity.
ARM B: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle and TTI-622 IV over 60-90 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT scans or CT scans of the chest, abdomen, and pelvis prior to cycle 3 and every 4 cycles thereafter. If no disease progression after cycle 12, patients then receive pembrolizumab IV over 30 minutes on days 1 of each cycle and TTI-622 IV over 60-90 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 23 cycles in the absence of disease progression or unacceptable toxicity.
After completion of the study treatment, patients are followed every 6 months for up to 2 years from registration.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Recruiting
- University of Iowa
-
Contact:
- Jussara Hagen
- Phone Number: 319-356-4200
- Email: jussara-hagen@uiowa.edu
-
Principal Investigator:
- Eric Mou, M.D.
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic
-
Contact:
- Clinical Trials Referral Office
- Phone Number: 855-776-0015
- Email: mayocliniccancerstudies@mayo.edu
-
Principal Investigator:
- Stephen M. Ansell, M.D., Ph.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age >= 18 years
Documented CD20+ mature B-cell neoplasm according to World Health Organization (WHO) classification (Swerdlow et al., 2016) as one of the following:
Diffuse large B-cell lymphoma not otherwise specified (NOS) including
- Transformed lymphoma
- Richter's transformation
- Germinal center B-cell type
- Activated B-cell type
- High-grade B-cell lymphoma (HGBCL), NOS
- Primary mediastinal (thymic) large B-cell lymphoma
- Patients with "double-hit" or "triple-hit" diffuse large B-cell lymphoma (DLBCL) (technically as HGBCL, with MYC and BCL2 and/or BCL6 rearrangements)
- Follicular lymphoma 3B
- T-cell/histiocyte-rich large B cell lymphoma
- Large B-cell lymphoma with IRF4 rearrangement
- Primary cutaneous DLBCL, leg type
- Epstein-Barr virus (EBV) positive DLBCL, NOS
- DLBCL associated with chronic inflammation
- Intravascular large B-cell lymphoma
- ALK positive large B-cell lymphoma
- Relapsed, progressive and/or refractory disease (Cheson et al., 2007) following treatment with an anti-CD20 monoclonal antibody (e.g., rituximab) in combination with chemotherapy
Measurable disease as defined below:
- Fluorodeoxyglucose (FDG)-avid lymphomas: Measurable disease with computerized tomography (CT) (or magnetic resonance imaging [MRI]) scan with involvement of 2 or more clearly demarcated lesions/nodes with a long axis > 1.5 cm and short axis > 1.0 cm (or 1 clearly demarcated lesion/node with a long axis > 2.0 cm and short axis >= 1.0 cm) AND FDG positron emission tomography (PET) scan that demonstrates positive lesion(s) compatible with CT (or MRI) defined anatomical tumor sites
- FDG-nonavid lymphomas: Measurable disease with CT (or MRI) scan with involvement of 2 or more clearly demarcated lesions/nodes with a long axis > 1.5 cm and short axis > 1.0 cm or 1 clearly demarcated lesion/node with a long axis > 2.0 cm and short axis >= 1.0 cm.
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1
- >= 4 weeks from last dose of anti-CD20 targeting therapy
- >= 12 weeks post chimeric antigen receptor (CAR) T-cell therapy
- Resolution of all adverse events due to prior therapy to =< Grade 1 or baseline NOTE: Patients with =< Grade 2 neuropathy may be eligible. Patients with endocrine-related adverse events (AEs) Grade =< 2 requiring treatment or hormone replacement may be eligible
- If receiving glucocorticoid treatment at screening, treatment must be tapered down and administered with a maximum of 10 mg daily in the last 14 days prior to registration
- Absolute neutrophil count (ANC) >= 500/mm^3; growth factor support allowed in case of bone marrow involvement (obtained =< 7 days prior to registration)
- Absolute lymphocyte count >= 200/mm^3 (obtained =< 7 days prior to registration)
- Platelet count >= 75,000/mm^3 (obtained =< 7 days prior to registration)
- Hemoglobin >= 8.0 g/dL (obtained =< 7 days prior to registration)
- International normalized ratio (INR) or activated partial thromboplastin time (aPTT) =< 1.5 × upper limit of normal (ULN) unless participant is receiving anticoagulant therapy as long as prothrombin time (PT) or aPTT is within therapeutic range of intended use of anticoagulants (obtained =< 7 days prior to registration)
- Total bilirubin =< 1.5 x upper limit of normal (ULN), unless due to Gilbert's disease (direct bilirubin [bili] =< ULN) (obtained =< 7 days prior to registration)
- Aspartate transaminase (AST/serum glutamic oxaloacetic transaminase [SGOT]) and alanine transaminase (ALT/serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x ULN (obtained =< 7 days prior to registration)
- Calculated creatinine clearance >=30 mL/min using the Cockcroft-Gault formula (obtained =< 7 days prior to registration)
- Provide informed written consent
- Negative pregnancy test done =< 3 days prior to registration, for persons of childbearing potential only
- Female of childbearing must agree to use a highly effective method of contraception during the treatment and for 120 days after the last dose of study treatment
- Male participants with female partners of childbearing potential must agree to refrain from donating sperm and one of the conception methods during the treatment and for 120 days after last dose study treatment
- Willing to return to the enrolling institution for follow-up (during the active monitoring phase of the study)
- Willing to provide mandatory tissue and blood samples for correlative research purposes
Exclusion Criteria:
- Primary central nervous system (CNS) lymphoma or known CNS involvement by lymphoma at screening as confirmed by magnetic resonance imaging (MRI)/computed tomography (CT) scan (brain) and, if clinically indicated, by lumbar puncture
Known past or current malignancy other than inclusion diagnosis, except for:
- Cervical carcinoma of Stage 1B or less
- Non-invasive basal cell or squamous cell skin carcinoma
- Non-invasive, superficial bladder cancer
- Prostate cancer with a current prostate specific antigen (PSA) level < 0.1 ng/mL
- Any curable cancer with a complete response (CR) of > 2 years duration
- Received < 2 prior systemic anti-cancer therapy including investigational agents =< 4 weeks or =< 5 half-lives, whichever is shorter, prior to registration
- Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX-40, CD137) =< 4 weeks prior to registration
Known clinically significant cardiac disease, including:
- Onset of unstable angina pectoris within 6 months of signing informed consent form (ICF)
- Acute myocardial infarction within 6 months of signing ICF
- Congestive heart failure (grade III or IV as classified by the New York Heart Association and/or known decrease ejection fraction of < 45%)
- Chronic ongoing infectious diseases (except hepatitis B or hepatitis C) requiring treatment (excluding prophylactic treatment) at the time of enrollment or =< the previous 2 weeks
- Confirmed history or current autoimmune disease or other diseases resulting in permanent immunosuppression or requiring permanent immunosuppressive therapy or primary immunodeficiency disorder. Low-dose steroids (=< 10 mg daily of prednisone equivalent) is allowed
- Seizure disorder requiring therapy (such as steroids or anti-epileptics)
- Autologous hematopoietic stem cell transplant (HSCT) =< 100 days prior or any prior allogeneic HSCT or solid organ transplantation
- Known human immunodeficiency virus (HIV) infection
- Exposed to live or live attenuated vaccine =< 4 weeks prior to registration
Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:
- Pregnant persons
- Nursing persons
- Persons of childbearing potential who are unwilling to employ adequate contraception
- Patient has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
- Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
Uncontrolled intercurrent illness including, but not limited to:
- ongoing or active infection
uncontrolled infection requiring ongoing antibiotics
- symptomatic congestive heart failure
- unstable angina pectoris
- cardiac arrhythmia
- or psychiatric illness/social situations that would limit compliance with study requirements
- known substance abuse disorder
- Known hypersensitivity to pembrolizumab
- Major surgery other than diagnostic surgery =< 4 weeks prior to registration
- Prior radiation therapy =< 2 weeks prior to registration or who has not recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. Note: A 1-week washout is permitted for palliative radiation (=< 2 weeks of radiotherapy) to non-CNS disease
- Active autoimmune disease such as Crohn's disease, rheumatoid arthritis, Sjogren's disease, systemic lupus erythematosus, or similar conditions requiring systemic treatment =< the past 3 months or a documented history of clinically severe autoimmune disease/syndrome difficult to control in the past.
EXCEPTIONS:
- Vitiligo or resolved childhood asthma/atopy
- Intermittent use of bronchodilators or local steroid injections
- Hypothyroidism stable on hormone replacement,
- Diabetes stable with current management
- History of positive Coombs test but no evidence of hemolysis
- Psoriasis not requiring systemic treatment
Conditions not expected to recur in the absence of an external trigger
- Has a known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known active hepatitis C virus (HCV) (defined as HCV ribonucleic acid [RNA] is detected) infection
- Prior anti CD47 therapy
- Active use of anticoagulant like warfarin. Use of low molecular weight heparin and factor Xa inhibitors will be permitted on case by case basis. There will be no restriction for daily aspirin < 81mg daily
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A (pembrolizumab, TTI-621)
Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle and TTI-621 IV over 60-120 minutes on day 1 of each cycle.
Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
Patients also undergo PET/CT scans or CT scans of the chest, abdomen, and pelvis prior to cycle 3 and every 4 cycles thereafter.
If no disease progression after cycle 12, patients then receive pembrolizumab IV over 30 minutes on days 1 of each cycle and TTI-621 IV over 60-120 minutes on day 1 of each cycle.
Treatment repeats every 21 days for up to 23 cycles in the absence of disease progression or unacceptable toxicity.
|
Given IV
Other Names:
Undergo correlative studies
Other Names:
Undergo PET/CT scans
Other Names:
Undergo PET/CT or CT scans of the chest, abdomen, and pelvis
Other Names:
Given IV
Other Names:
|
Experimental: Arm B (pembrolizumab, TTI-622)
Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle and TTI-622 IV over 60-90 minutes on day 1 of each cycle.
Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
Patients also undergo PET/CT scans or CT scans of the chest, abdomen, and pelvis prior to cycle 3 and every 4 cycles thereafter.
If no disease progression after cycle 12, patients then receive pembrolizumab IV over 30 minutes on days 1 of each cycle and TTI-622 IV over 60-90 minutes on day 1 of each cycle.
Treatment repeats every 21 days for up to 23 cycles in the absence of disease progression or unacceptable toxicity.
|
Given IV
Other Names:
Undergo correlative studies
Other Names:
Undergo PET/CT scans
Other Names:
Undergo PET/CT or CT scans of the chest, abdomen, and pelvis
Other Names:
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recommended phase 2 dose of TTI-621 and TTI-622 when given in combination with pembrolizumab (Safety run-in)
Time Frame: Up to 6 weeks
|
Defined as the highest dose for which at most 1 out of 6 subjects experience significant toxicity during the 6-week safety assessment period.
Toxicity will be measured per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5. Significant toxicity is defined as an adverse event occurring during the first cycle of treatment that is possibly, probably, or definitely related to study treatment.
|
Up to 6 weeks
|
Overall response (Phase 2)
Time Frame: Up to 2 years
|
A success is defined as an objective status of partial metabolic response (PMR) or complete metabolic response (CMR) by positron emission tomography-computed tomography (PET-CT) based criteria at any time.
The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients.
95% confidence intervals for the true success proportion will be calculated according to the approach of Duffy and Santner (1987).
Note: For patients where PET/CT scan was not available due to insurance coverage and who received a CT scan only, they will still be considered evaluable for the primary endpoint and will be included in the denominator for estimating overall response rate.
In these patients, the CT-based responses will be reported descriptively.
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of response (DOR) (Phase 2)
Time Frame: Up to 2 years
|
Defined for all evaluable patients who have achieved an objective response as the date at which the patient's objective status is first noted to be either a CMR or PMR to first documentation of disease progression.
DOR will be descriptively summarized.
|
Up to 2 years
|
Progression-free survival (PFS) (Phase 2)
Time Frame: Time from registration to first documentation of disease progression (progressive metabolic disease [PMD] or progressive disease [PD]) or death due to any cause in the absence of documented progression, assessed up to 2 years
|
For patients who receive subsequent treatment before disease progression, the patient will be censored at their last disease assessment.
The distribution of PFS will be estimated using the method of Kaplan-Meier (1958).
Median and landmark estimates along with two-sided 95% confidence intervals will be reported.
|
Time from registration to first documentation of disease progression (progressive metabolic disease [PMD] or progressive disease [PD]) or death due to any cause in the absence of documented progression, assessed up to 2 years
|
Overall survival (OS) (Phase 2)
Time Frame: Time from registration to death due to any cause, assessed up to 2 years
|
Patients still alive by the analysis cutoff will be censored at their last date known to be alive.
The distribution of OS will be estimated using the method of Kaplan-Meier.
Median and landmark estimates along with two-sided 95% confidence intervals will be reported.
|
Time from registration to death due to any cause, assessed up to 2 years
|
Incidence of adverse events (AEs) (Phase 2)
Time Frame: Up to 2 years
|
All eligible patients that have initiated treatment will be considered evaluable for assessing AE rate(s).
The maximum grade for each type of AE will be recorded for each patient, and frequency tables will be reviewed to determine patterns.
Additionally, the relationship of the AE(s) to the study treatment will be taken into consideration.
|
Up to 2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Stephen M, Ansell, M.D., Ph.D., Mayo Clinic in Rochester
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Disease Attributes
- Lymphoma
- Lymphoma, Follicular
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Inflammation
- Recurrence
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Pembrolizumab
- Immunoglobulin G
Other Study ID Numbers
- MC200802 (Mayo Clinic in Rochester)
- NCI-2022-06277 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent B-Cell Non-Hodgkin Lymphoma
-
National Cancer Institute (NCI)RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin LymphomaUnited States
-
Nathan DenlingerBristol-Myers SquibbRecruitingB-Cell Non-Hodgkin Lymphoma-Recurrent | Diffuse Large B-Cell Lymphoma-Recurrent | Follicular Lymphoma-Recurrent | High Grade B-Cell Lymphoma-Recurrent | Primary Mediastinal Large B-Cell Lymphoma-Recurrent | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnRecurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent High Grade B-Cell Lymphoma | Recurrent Aggressive Non-Hodgkin Lymphoma | Recurrent Burkitt Lymphoma | Recurrent Transformed B-Cell Non-Hodgkin LymphomaUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell LymphomaUnited States
-
Mayo ClinicNot yet recruitingIndolent B-Cell Non-Hodgkin Lymphoma | Recurrent Indolent Non-Hodgkin Lymphoma | Refractory Indolent Non-Hodgkin Lymphoma | Recurrent Indolent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent B-Cell Non-Hodgkin LymphomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingDiffuse Large B-Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Mantle Cell Lymphoma | B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Transformed Non-Hodgkin LymphomaUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingRefractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent... and other conditionsUnited States
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); Memorial Sloan Kettering Cancer CenterNot yet recruitingHIV Infection | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent... and other conditions
Clinical Trials on Pembrolizumab
-
Incyte CorporationMerck Sharp & Dohme LLCCompletedMelanomaUnited States, France, Italy, United Kingdom, Spain, Belgium, Israel, Mexico, Japan, Canada, Netherlands, Sweden, Korea, Republic of, Australia, Russian Federation, Chile, Germany, Poland, Ireland, New Zealand, Denmark, Switzerland, South Africa
-
Merck Sharp & Dohme LLCCompletedMelanomaAustralia, South Africa, Spain, Sweden
-
University Medical Center GroningenCompleted
-
Acerta Pharma BVMerck Sharp & Dohme LLCCompletedMetastatic Urothelial CarcinomaUnited States
-
HUYABIO International, LLC.Active, not recruitingNon Small Cell Lung CancerUnited States
-
Prof. Dr. Matthias PreusserUnknownPrimary Central Nervous System LymphomaAustria
-
Sichuan UniversityGeneplus-Beijing Co. Ltd.RecruitingNon-small Cell Lung CancerChina
-
Chinese University of Hong KongCompletedAcral Lentiginous MelanomaHong Kong
-
Yonsei UniversityNot yet recruitingMucosal Melanoma | Acral MelanomaKorea, Republic of
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Merck Sharp & Dohme LLC; PTC TherapeuticsRecruitingColorectal Cancer | Endometrium CancerNetherlands